JP2019518063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518063A5 JP2019518063A5 JP2018566377A JP2018566377A JP2019518063A5 JP 2019518063 A5 JP2019518063 A5 JP 2019518063A5 JP 2018566377 A JP2018566377 A JP 2018566377A JP 2018566377 A JP2018566377 A JP 2018566377A JP 2019518063 A5 JP2019518063 A5 JP 2019518063A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- hetaryl
- heterocyclyl
- cycloalkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *[*+]1N=C(*)c(cc2CN3*)c1cc2NC3=O Chemical compound *[*+]1N=C(*)c(cc2CN3*)c1cc2NC3=O 0.000 description 4
- FTYFEXZBNYBQEY-UHFFFAOYSA-N CCNC(Nc(cc1)nc2c1ncc(-c1c[n](CC(C)C)nc1)n2)=O Chemical compound CCNC(Nc(cc1)nc2c1ncc(-c1c[n](CC(C)C)nc1)n2)=O FTYFEXZBNYBQEY-UHFFFAOYSA-N 0.000 description 1
- WUTVMXLIGHTZJC-UHFFFAOYSA-N Cc1c(-c2c[nH]c(C(NC(CO)c3cccc(Cl)c3)=O)c2)nc(Nc(c(Cl)c2)ccc2F)nc1 Chemical compound Cc1c(-c2c[nH]c(C(NC(CO)c3cccc(Cl)c3)=O)c2)nc(Nc(c(Cl)c2)ccc2F)nc1 WUTVMXLIGHTZJC-UHFFFAOYSA-N 0.000 description 1
- AIMJWAQVOUDRCO-ZSOIEALJSA-N NCCCCC(C(/C(/S1)=C/c(cc2)cc3c2OCO3)=O)C1=O Chemical compound NCCCCC(C(/C(/S1)=C/c(cc2)cc3c2OCO3)=O)C1=O AIMJWAQVOUDRCO-ZSOIEALJSA-N 0.000 description 1
- XVECMUKVOMUNLE-UHFFFAOYSA-N Nc1n[nH]c2c1cc(-c1c(cccc3)[n]3nc1-c1ccccc1)nn2 Chemical compound Nc1n[nH]c2c1cc(-c1c(cccc3)[n]3nc1-c1ccccc1)nn2 XVECMUKVOMUNLE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352533P | 2016-06-20 | 2016-06-20 | |
| US62/352,533 | 2016-06-20 | ||
| US201662428379P | 2016-11-30 | 2016-11-30 | |
| US62/428,379 | 2016-11-30 | ||
| US201762502996P | 2017-05-08 | 2017-05-08 | |
| US62/502,996 | 2017-05-08 | ||
| PCT/US2017/038084 WO2017222958A1 (en) | 2016-06-20 | 2017-06-19 | Treatment of squamous cell carcinomas with inhibitors of erk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518063A JP2019518063A (ja) | 2019-06-27 |
| JP2019518063A5 true JP2019518063A5 (enExample) | 2020-07-16 |
Family
ID=60783255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566377A Pending JP2019518063A (ja) | 2016-06-20 | 2017-06-19 | Ｅｒｋ阻害剤を用いた扁平上皮細胞癌の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190192517A1 (enExample) |
| EP (1) | EP3471717A4 (enExample) |
| JP (1) | JP2019518063A (enExample) |
| CN (1) | CN109661228A (enExample) |
| TW (1) | TW201805000A (enExample) |
| WO (1) | WO2017222958A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017139727A (ru) | 2015-06-15 | 2019-07-16 | АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи | Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования |
| AU2017372856B9 (en) | 2016-12-05 | 2024-01-04 | Pharmacosmos Holding A/S | Preservation of immune response during chemotherapy regimens |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| EP3601249A4 (en) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| CN110546150B (zh) * | 2017-10-19 | 2021-12-21 | 江苏豪森药业集团有限公司 | 含吡唑基的三并环类衍生物、其制备方法和应用 |
| CN111821434A (zh) * | 2019-04-17 | 2020-10-27 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 |
| WO2020061103A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| WO2020200161A1 (zh) * | 2019-04-02 | 2020-10-08 | 上海翰森生物医药科技有限公司 | 含吲唑基的三并环类衍生物的盐及其晶型 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| EP4322956A4 (en) * | 2021-04-16 | 2025-03-19 | Erasca, Inc. | Uses of heterocyclic inhibitors of erk1/2 |
| CN121197167A (zh) * | 2025-10-24 | 2025-12-26 | 中国人民解放军军事科学院军事医学研究院 | 一种药物组合物及其在治疗结肠癌中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7151161B1 (en) * | 1998-01-13 | 2006-12-19 | Oscient Pharmaceuticals Corporation | Human genes of chromosome 11q13.3 |
| TW200536536A (en) * | 2004-02-25 | 2005-11-16 | Schering Corp | Pyrazolotriazines as kinase inhibitors |
| JP2006094733A (ja) * | 2004-09-28 | 2006-04-13 | As One Corp | 癌の検出方法 |
| ES2448491T3 (es) * | 2006-03-02 | 2014-03-14 | The Ohio State University Research Foundation | Perfil de expresión de microARN asociado con cáncer de páncreas |
| WO2013106812A1 (en) * | 2012-01-12 | 2013-07-18 | Board Of Regents, The University Of Texas System | Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| SMT201800205T1 (it) * | 2013-10-03 | 2018-05-02 | Kura Oncology Inc | Inibitori di erk e metodi d'uso |
-
2017
- 2017-06-19 CN CN201780051014.8A patent/CN109661228A/zh active Pending
- 2017-06-19 JP JP2018566377A patent/JP2019518063A/ja active Pending
- 2017-06-19 TW TW106120308A patent/TW201805000A/zh unknown
- 2017-06-19 EP EP17815990.1A patent/EP3471717A4/en not_active Withdrawn
- 2017-06-19 WO PCT/US2017/038084 patent/WO2017222958A1/en not_active Ceased
-
2018
- 2018-12-17 US US16/222,398 patent/US20190192517A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10407726B2 (en) | miRNA biomarkers for radiation biodosimetry | |
| US20120264626A1 (en) | MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof | |
| CN103608683A (zh) | Hedgehog抑制剂治疗的生物标志物 | |
| US20110117563A1 (en) | Antiviral therapy | |
| JP2010528659A (ja) | 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法 | |
| US20130059749A1 (en) | Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy | |
| JP2015531590A5 (enExample) | ||
| JP2011188853A5 (enExample) | ||
| TW201739919A (zh) | 患者特異性新抗原決定基之高通量識別以作為用於癌症免疫療法之治療劑 | |
| JP2019514387A5 (enExample) | ||
| CN103402517A (zh) | 使用braf抑制剂的治疗方法 | |
| JP2015530868A5 (enExample) | ||
| JP2018527886A5 (enExample) | ||
| CN102016031B (zh) | 高血压易感基因组的鉴定 | |
| US20210348238A1 (en) | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy | |
| CA2907124A1 (en) | Assay for predictive biomarkers | |
| CN104884636B (zh) | Hbv对肝细胞癌癌症患者临床结果的影响 | |
| CA2660622A1 (en) | Rig-i mutations and uses thereof in diagnostic and therapeutic virus-dependent immune applications | |
| Kim et al. | Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11) | |
| JP6348699B2 (ja) | インターフェロン治療効果予測方法 | |
| JP2014513975A (ja) | 結腸癌を有する患者の生存期間のｋｉａａ１４５６発現による予測 | |
| US11952631B2 (en) | Diagnostics and therapy for human respiratory syncytial virus | |
| CN109937260A (zh) | 提供流感感染预后的组合物和方法 | |
| Scelo et al. | Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer | |
| US20130143207A1 (en) | Methods and compositions for identifying biomarkers useful in characterizing biological states |